The present study is the first to investigate the role of genetic variation in IGF signaling and breast cancer risk in women carrying deleterious mutations in BRCA1 and BRCA2. We identified significant associations for variants in IGF1R and IRS1 for BRCA1 carriers and for variants in IGFBP2 for BRCA2 carriers. This evidence concerns the gene IRS1 and breast carcinoma.